Multiple Sclerosis Patient-Reported Outcomes Study Shows Improvements In Quality Of Life Among Patients After 1 Year Of Treatment With TYSABRI

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measur...

Read the original post at Psychology / Psychiatry News From Medical News Today ...

Share your thoughts.